Clinical Trials Logo

Mortality clinical trials

View clinical trials related to Mortality.

Filter by:

NCT ID: NCT03289325 Completed - Quality of Life Clinical Trials

Dexmedetomidine and Long-term Outcomes in Elderly Patients After Cardiac Surgery

Start date: December 5, 2016
Phase: N/A
Study type: Interventional

A retrospective study showed that intraoperative dexmedetomidine administration was associated with decreased risk of 1-year mortality after cardiac surgery. In a previous randomized controlled trial, 285 elderly patients undergoing cardiac surgery were randomized to receive either perioperative dexmedetomidine or placebo (normal saline) administration. The purpose of this 6-year follow-up study is to investigate whether perioperative dexmedetomidine can improve long-term outcomes in those recruited elderly patients after cardiac surgery.

NCT ID: NCT03270930 Completed - Emergencies Clinical Trials

Operative Duration as a Predictor of Mortality in Pediatric Emergency Surgery

Start date: April 1, 2015
Phase: N/A
Study type: Observational

Introduction Operative duration is an important but under-studied predictor of mortality in emergency laparotomies. Aims & Objectives The objective of this study was to quantify the effect of duration of emergency laparotomy in children on mortality and to identify a rough cut-off duration of laparotomy to serve as a guide to plan the laparotomy to optimize pediatric surgical patient outcome.

NCT ID: NCT03245658 Withdrawn - Mortality Clinical Trials

The Effect of Cannabis in Pancreatic Cancer

Start date: October 6, 2017
Phase: Phase 2
Study type: Interventional

Cannabinoids are known to increase appetite, but THC components have psychogenic properties too. CBD is the main component in the plant, and have only minimal psychogenic effects. The aim was to test the appetite stimulating effects of CBD in patients with pancreatic cancer in palliative treatment.

NCT ID: NCT03234101 Active, not recruiting - Cancer Clinical Trials

Meta-Analyses of Low-risk Lifestyle Behaviours and Patient Important Outcomes

Start date: June 2016
Phase: N/A
Study type: Observational

Public health policy is universal in recommending the adoption of low risk low-risk lifestyle behaviors for health promotion and prevention of chronic or non-communicable diseases (NCDs).These behaviors generally include achieving and maintaining a healthy body weight, healthy diet, regular physical activity, smoking cessation, moderate alcohol intake, and adequate sleep. While there is a general consensus that adherence to any one of these low-risk lifestyle behaviors is associated with benefit, it is not clear if adherence to multiple behaviors would result in a larger benefit across different groups of people, conditions, and chronic disease outcomes. The Canadian Cardiovascular Society (CCS), as part of the Dyslipidemia Guidelines Update, commissioned a series of systematic reviews and meta-analyses (a type of knowledge synthesis) using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to quantify the benefit of adherence to multiple low-risk lifestyle behaviors in relation to patient-important chronic disease outcomes (risk of cardiovascular disease, diabetes, cancer, and death) and assesses the quality and strength of the evidence for this benefit.

NCT ID: NCT03220763 Active, not recruiting - Mortality Clinical Trials

Eating Away From Home and Mortality

Start date: July 2016
Phase: N/A
Study type: Observational

The proposed study will test the hypothesis that frequency of eating away from home meals is independently related to the prospective risk of mortality in the US population. The study will use public-domain mortality linked data from US national Surveys to address this question.

NCT ID: NCT03192410 Active, not recruiting - Clinical trials for Cardiovascular Diseases

Prospective Cohort Study of 4,837 Post-myocardial Infarction Patients (Alpha Omega Cohort)

Start date: April 2002
Phase: N/A
Study type: Observational

The Alpha Omega Cohort is a prospective study of 4,837 state-of-the-art drug-treated Dutch patients aged 60-80 years who had a clinically diagnosed myocardial infarction up to 10 years before enrolment. During the first 40 months of follow-up, patients took part in an experimental study of low doses n-3 fatty acids (Alpha Omega Trial, ClinicalTrials.gov NCT00127452). At baseline (2002-2006), data on medical history, medication use, diet, lifestyle and other factors were collected by means of questionnaires. Patients were physically examined by trained research nurses and blood samples were obtained. Follow-up for vital status and cause-specific mortality is ongoing. The trial was approved by a central medical ethics committee (Haga Hospital, The Hague, The Netherlands) and all patients provided written informed consent.

NCT ID: NCT03166696 Active, not recruiting - Clinical trials for Myocardial Infarction

Acute Myocardial Infarction and Acute Cerebral Infarction (AMIAC) Registry and Follow-up

AMIAC
Start date: January 3, 2000
Phase: N/A
Study type: Observational [Patient Registry]

A registry of consecutive patients who were admitted and diagnosed with acute myocardial infarction or acute cerebral infarction were conducted at the Guangdong General Hospital or the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Yue Bei People's Hospital, China, between January 2000 and December 2016. The adverse clinical outcomes, including all-cause mortality, were followed from the date of admission for acute myocardial infarction or acute cerebral infarction until study end (December 31, 2016). All-cause mortality, including the date of death, was identified from the electronic hospitalization data, phone follow-up, and confirmed by the household registration (HUKOU) system, a record of registration required by law in China. Baseline characteristics, including major treatment of acute myocardial infarction or acute cerebral infarction, estimated glomerular filtration rate (eGFR) and proteinuria, were collected. Demographic data were determined from the electronic hospitalization data and electronic hospital discharge records. All comorbid conditions were identified using International Statistical Classification of Diseases, Tenth Revision (ICD-10), coding algorithms applied to electronic physician claims and electronic hospital discharge records. Life style (smoking), treatment regimen at discharge, including angiotensin-converting enzyme inhibitor (ACEI), angiotensin II receptor blocker (ARB), were determined from the electronic hospitalization data.

NCT ID: NCT03155659 Completed - Mortality Clinical Trials

Fish, Polyunsaturated Fatty Acids Intake and Mortality

Start date: January 1989
Phase:
Study type: Observational

Data linking fish, polyunsaturated fatty acids intake and mortality are lacking and conflicting. We aim to use data from the China Health and Nutrition Survey (CHNS) and National Health and Nutrition Examination Survey (NHANES) to investigate the associations of fish and polyunsaturated fatty acids (PUFA) intake with mortality in Chinese and US populations. The study findings will be informative for addressing the role of fish and specific PUFA in human health and improve basis for dietary recommendations.

NCT ID: NCT03152734 Completed - Mortality Clinical Trials

Periinterventional Outcome Study in the Elderly

POSE
Start date: October 1, 2017
Phase:
Study type: Observational

The POSE study will predict critical stages and outcome in a large sample of all surgical and non-surgical interventional patients ≥80 years of age in Europe.

NCT ID: NCT03118895 Completed - Clinical trials for Myocardial Infarction

Leaders Free III: BioFreedom™ Clinical Trial

Start date: November 8, 2017
Phase: N/A
Study type: Interventional

A study evaluating the safety and efficacy of the BioFreedom™ Biolimus A9™ coated Cobalt Chromium coronary stent system in patients at high risk of bleeding